This clinical trial is focused on studying the effectiveness and safety of a new treatment for Moderate to Severe Plaque Psoriasis, a skin condition that causes red, scaly patches on the skin. The study will test a medication called ESK-001, which is taken as a tablet by mouth. The trial will compare the effects of ESK-001 with a placebo and another medication called Otezla, which contains the active ingredient apremilast.
The purpose of the study is to determine if ESK-001 is more effective than a placebo after 16 weeks of treatment. Participants will be randomly assigned to receive either ESK-001, Otezla, or a placebo. The study will last up to 24 weeks, during which participants will take the medication orally. The trial aims to see improvements in the skin condition by measuring changes in the severity and extent of the psoriasis patches.
Throughout the study, participants will be monitored to assess the safety and effectiveness of the treatments. The trial will help researchers understand if ESK-001 can provide better outcomes for people with moderate to severe plaque psoriasis compared to existing treatments. This study is an important step in finding new and effective ways to manage this chronic skin condition.
Austria 
Estonia 
France 
Germany 
Hungary 
Latvia 
Poland 
Romania 
Spain 
